Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa

Coronary Artery Disease

Volumn 7, Issue 1, 1996, Pages 57-62

  Speidel, Christopher M ^a   Thornton, J Daryl ^a   Meng, Yuan Yuan ^a   Eisenberg, Paul R ^a   Edgington, Thomas S ^b   Abendschein, Dana R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

coagulation; thrombin; thrombolysis; tissue factor

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; FIBRIN; FIBRINOPEPTIDE A; MONOCLONAL ANTIBODY; PROCOAGULANT; THROMBIN; THROMBOPLASTIN; VITAMIN K GROUP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INJURY; AORTA THROMBOSIS; ARTERY PERFUSION; ARTICLE; CONTROLLED STUDY; EFFLUENT; FIBRIN FORMATION; NONHUMAN; PLASMA; PRIORITY JOURNAL; RABBIT;

ANIMALS; AORTA, ABDOMINAL; BLOOD COAGULATION; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; FACTOR VIIA; FACTOR XA; FIBRINOPEPTIDE A; HUMANS; MICROSCOPY, ELECTRON, SCANNING; PROTHROMBIN; RABBITS; THROMBIN; THROMBOLYTIC THERAPY; THROMBOPLASTIN; THROMBOSIS;

EID: 0029984074     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, et al.: The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) trial. Circulation 1987, 75:817-829.
2. Fry ETA, Sobel B: Coronary thrombolysis. In Progress in Cardiology . Edited by Zipes DP, Rowlands DJ, Philadelphia: Lea & Febiger, 1990, 199-239.
3. Chesebro JH, Badimon L, Fuster V: New approaches to treatment of myocardial infarction. Am J Cardiol 1990, 65:12C-19C.
4. Fuster V, Stein B, Badimon L, Chesebro JH: Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction. J Am Coll Cardiol 1988, 12:78A-84A.
5. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
6. Haskel EJ, Prager NA, Sobel BE, Abendschein DR: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991, 83:1048-1056.
7. Rigel DF, Olson RW, Lappe RW: Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res 1993, 72:1091-1102.
8. Topol EJ, George BS, Kereiakes DJ: A randomized controled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989, 79:281-286.
9. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994, 23:993-1003.
10. Lee LV: Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995, 75:7-13.
11. Lidon R-M, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, et al.: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994, 89:1567-1572.
12. Rote WE, Mu D-X, Bates ER, Nedelman MA, Lucchesi BR: Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol 1994, 23:203-211.
13. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993, 91:1877-1883.
14. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al.: The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993, 92:1207-1212.
15. Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989, 134:1087-1097.
16. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y Hoffman T: Evidence for the presence of tissue factor activity on subendothelium. Blood 1989, 73:968-975.
17. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989, 86:2839-2843.
18. Nemerson Y: The interaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966, 5:601-608.
19. Østerud B, Rapaport SI: Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977, 74:5260-5264.
20. Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, et al.: Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation 1989, 80:1775-1782
21. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR: Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993, 22:296-301.
22. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR: Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995, 92: 3323-3330.
23. Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990, 248:593-596.
24. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP: The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988, 71:335-343.
25. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS: Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985, 71:912-918.
26. Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, et al.: Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991, 84:821-827.
27. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, et al.: A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994, 74:56-63.
28. Abendschein DR, Meng YY, Torr-Brown SR, Sobel BE: Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995, 92:944-949.
29. Eisenberg PR, Sobel BE, Jaffe AS: Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992, 19:1065-1069.